Biocon Confirms Viatris North American Transition Will Complete By End Q3 2023

Aug 12, 2023

According to the Business Standard Biocon Biologics’ CEO has confirmed the transition of the North American part of Viatris’ global biosimilars business to Biocon will complete by the end of this quarter, less than a year after the companies signed a $3.34B acquisition of Viatris’ biosimilars business on 29 November 2022.  Biocon and Viatris have had a two-year transition services agreement in place following finalisation of the acquisition in November last year.  Biocon will also consider an IPO once Viatris is integrated.

On 5 July 2023, Biocon Biologics announced it had completed a third of the integration of Viatris’ biosimilars business in over 70 countries in ‘emerging markets’.

Print Page Mail Article